N-(4-Methyl-2-oxo-2H-chromen-7-yl)palmitamide | 1353576-61-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: N-(4-Methyl-2-oxo-2H-chromen-7-yl)palmitamide
• 英文别名: N-(4-methyl-2-oxochromen-7-yl)hexadecanamide
• CAS: 1353576-61-0
• 化学式: C₂₆H₃₉NO₃
• 分子量: 413.6
• InChiKey: ITQZQRAXGGXRRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  30
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。
• [EN] PIPERAZINYL METHANONE NAAA INHIBITORS<br/>[FR] INHIBITEURS DE PIPÉRAZINYL MÉTHANONE NAAA
  申请人：UNIV CALIFORNIA

  公开号：WO2017201103A1

  公开（公告）日：2017-11-23

  Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.

  本文披露了用于调节N-酰乙醇胺酸酰胺酶活性的组合物和方法，用于治疗病理状态，包括疼痛、炎症症状或神经退行性疾病。
• MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT
  申请人：FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：US20190135802A1

  公开（公告）日：2019-05-09

  Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolysing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.

  药物组合物构成一种作为N-酰乙醇胺水解酸酶（NAAA）抑制剂的化合物，可用于治疗和预防疼痛和炎症性疾病以及其他受益于脂肪酸乙醇胺调节的疾病，特别是棕榈酰乙醇胺（PEA）。该化合物用于抑制NAAA的方法以及治疗和预防疼痛和炎症的方法。
• Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA)
  申请人：The Regents of the University of California

  公开号：US20130281490A1

  公开（公告）日：2013-10-24

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了一种抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在低浓度下的PEA和OEA的水平的方法，这两种物质是NAAA的底物。本发明还提供了治疗炎症性疾病、疼痛和其他与PEA和OEA浓度降低相关的疾病的方法。
• DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)
  申请人：Fondazione Istituto Italiano Di Tecnologia

  公开号：US20160235707A1

  公开（公告）日：2016-08-18

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-乙酰基乙醇胺酸酰化酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在PEA和OEA两种NAAA底物的水平在浓度降低的情况下的方法。本发明还提供了用于治疗炎症性疾病和疼痛以及其他与PEA和OEA水平下降相关的疾病的方法。